Is tadalafil associated with decreased risk of major adverse cardiac events or venous thromboembolism in men with lower urinary tract symptoms?
- 25 April 2022
- journal article
- research article
- Published by Springer Nature in World Journal of Urology
- Vol. 40 (7) , 1799-1803
Abstract
Purpose To evaluate the association of tadalafil, a phosphodiesterase-5 inhibitor (PDE5I), with major adverse cardiac events (MACE) or venous thromboembolism (VTE) in men with lower urinary tract symptoms (LUTS). Methods Data was obtained from the TriNetX Research Network, ICD-10 codes were used to identify men with LUTS, MACE, and VTE. In addition, demographic characteristics and use of tadalafil or alpha-blocker was evaluated. Then, unbalanced and balanced association analyses was performed to assess the relation between tadalafil and/or alpha-blocker use with MACE/VTE. Results After participant selection, analysis included 821,592 men that did not use an alpha blocker or tadalafil, 5,004 men that used tadalafil but no alpha blocker, 327,482 men that used an alpha blocker but no tadalafil, and 6,603 men that used both an alpha blocker and tadalafil. On balanced analysis, tadalafil was independently associated with a decreased risk of MACE/VTE within a 3-year time period (OR = 0.59, 95%CI 0.49–0.70, p < 0.0001). Among men with a history of alpha blocker use, tadalafil use was also independently associated with a decreased risk of MACE or VTE, both before and after controlling for potentially confounding variables (OR = 0.57, 95%CI: 0.50–0.66; p < 0.0001). Conclusions In our study, tadalafil was associated with a decreased risk of MACE/VTE in men with LUTS with and without a history of alpha blocker use. It is time to perform further long-term prospective randomized studies to further analyze the cardiovascular effects of PDE5Is as combination treatment with alpha blockers in the management of LUTS.Keywords
Funding Information
- National Institutes of Health (R01 DK130991)
This publication has 31 references indexed in Scilit:
- Confounder Summary Score2015
- Direct Vasodilators and Sympatholytic AgentsJournal of Cardiovascular Pharmacology and Therapeutics, 2015
- Increase of Framingham cardiovascular disease risk score is associated with severity of lower urinary tract symptomsBJU International, 2015
- Comparative Effectiveness and Safety of Oral Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction: A Systematic Review and Network Meta-analysisEuropean Urology, 2013
- An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational StudiesMultivariate Behavioral Research, 2011
- Age- and Gender-Specific Prevalence of Cardiovascular Risk Factors in 40 102 Patients With First-Ever Ischemic StrokeStroke, 2010
- Cardiovascular Safety Update of Tadalafil: Retrospective Analysis of Data from Placebo-Controlled and Open-Label Clinical Trials of Tadalafil With As Needed, Three Times-per-Week or Once-a-Day DosingThe American Journal of Cardiology, 2006
- Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunctionExpert Opinion on Pharmacotherapy, 2005
- Quantitation of tadalafil in human plasma by liquid chromatography–tandem mass spectrometry with electrospray ionizationJournal of Chromatography B, 2004
- THE EFFICACY AND SAFETY OF TADALAFIL IN UNITED STATES AND PUERTO RICAN MEN WITH ERECTILE DYSFUNCTIONJournal of Urology, 2004